Novel drug candidates for treating heart failure and cardiac fibrosis

In this project, we have developed early lead candidates for the treatment of heart failure and fibrosis, based on a novel and promising therapeutic principle. Initially, we identified promising starting points for the development of new drug candidates using advanced computational models. These models predict how molecules bind to the therapeutic target, and the candidates were evaluated based on their predicted binding affinity and likelihood of inhibiting the target, as well as their patenting potential. Among the most promising candidates, we synthesized over 30 molecules and tested their ability to inhibit the target. Based on the results of these tests, we identified several early lead candidates that now serve as a solid foundation for further development. This outcome has validated the methodology we employ, played a critical role in attracting additional funding, and demonstrated that we are on the right track toward developing effective therapies. We have engaged in discussions with leading experts, potential investors, and representatives from the pharmaceutical industry. These conversations have resulted in tangible interest from investors who are considering financially supporting further development. Additionally, we have established connections with future collaborators, developed detailed plans for upcoming phases, and submitted new funding applications. Our project leader has also been accepted into the Women TechEU program, which supports female leaders in deep tech by offering mentorship, networking opportunities, and training.

Resultater fra prosjektet - Identifisert tidlige ledekandidater for videre utvikling (WP1-2) - Styrket proprietære ressurser for bruk i utvikling av legemiddelkandidater, inkludert databaser og datamodeller (WP1-2) - Testet syntetiseringsveier for legemiddelkandidatene (WP2) - Validering av strategi (WP1-3). - Styrket kompetanse, samarbeid og interaksjon i prosjektteamet (WP4). Effekter av prosjektet - Samfunnseffekt: Potensiale for å utvikle bedre behandlingsmuligheter for en stor pasientgruppe. - Næringsutvikling: Potensiale for å skape verdier fra forskning og styrke norsk legemiddelindustri. - Kompetansebygging: Økt ekspertise innen tidlig fase legemiddelutvikling.